Cutis is a peer-reviewed clinical journal for the dermatologist, allergist, and general practitioner published monthly since 1965. Concise clinical articles present the practical side of dermatology, helping physicians to improve patient care. Cutis is referenced in Index Medicus/MEDLINE and is written and edited by industry leaders.

Top Sections
Coding
Dermpath Diagnosis
For Residents
Photo Challenge
Tips
ct
Main menu
CUTIS Main Menu
Explore menu
CUTIS Explore Menu
Proclivity ID
18823001
Unpublish
Negative Keywords
ammunition
ass lick
assault rifle
balls
ballsac
black jack
bleach
Boko Haram
bondage
causas
cheap
child abuse
cocaine
compulsive behaviors
cost of miracles
cunt
Daech
display network stats
drug paraphernalia
explosion
fart
fda and death
fda AND warn
fda AND warning
fda AND warns
feom
fuck
gambling
gfc
gun
human trafficking
humira AND expensive
illegal
ISIL
ISIS
Islamic caliphate
Islamic state
madvocate
masturbation
mixed martial arts
MMA
molestation
national rifle association
NRA
nsfw
nuccitelli
pedophile
pedophilia
poker
porn
porn
pornography
psychedelic drug
recreational drug
sex slave rings
shit
slot machine
snort
substance abuse
terrorism
terrorist
texarkana
Texas hold 'em
UFC
Negative Keywords Excluded Elements
div[contains(@class, 'alert ad-blocker')]
section[contains(@class, 'nav-hidden')]
section[contains(@class, 'nav-hidden active')
Altmetric
DSM Affiliated
Display in offset block
Disqus Exclude
Best Practices
CE/CME
Education Center
Medical Education Library
Enable Disqus
Display Author and Disclosure Link
Publication Type
Clinical
Slot System
Featured Buckets
Disable Sticky Ads
Disable Ad Block Mitigation
Featured Buckets Admin
Show Ads on this Publication's Homepage
Consolidated Pub
Show Article Page Numbers on TOC
Expire Announcement Bar
Use larger logo size
Off
publication_blueconic_enabled
Off
Show More Destinations Menu
Disable Adhesion on Publication
Off
Restore Menu Label on Mobile Navigation
Disable Facebook Pixel from Publication
Exclude this publication from publication selection on articles and quiz
Gating Strategy
First Page Free
Challenge Center
Disable Inline Native ads
survey writer start date
Current Issue
Title
Cutis
Description

A peer-reviewed, indexed journal for dermatologists with original research, image quizzes, cases and reviews, and columns.

Current Issue Reference

Systemic Mastocytosis: Classification, Pathogenesis, Diagnosis, and Treatment

Article Type
Changed
Display Headline
Systemic Mastocytosis: Classification, Pathogenesis, Diagnosis, and Treatment


Case Report
A 46-year-old woman presented with a rash that had been present for more than 20 years but had progressed over the past 6 years and was associated with pruritus, burning, and blistering precipitated by temperature changes or anxiety. In addition, she had watery diarrhea for 5 years and also had been found to have osteopenia. She was a healthy-appearing woman with prominent facial erythema. Vital signs were normal. Skin examination revealed facial telangiectases as well as erythema and 2- to 4-mm reddish brown papules and macules on the extensor surfaces of the arms and thighs, chest, abdomen, and back, coalescing into plaques on the thighs (Figure). She had bilateral axillary lymphadenopathy. Liver and spleen were not palpable. Her hemoglobin level was 12.7 g/dL (reference range, 14.0–17.5 g/dL); white blood cell count was 5.2X109/L (reference range, 4.5–11.0X109/L) with 63 neutrophils, 36 lymphocytes, and 1 monocyte; and platelet count was 301X109/L (reference range, 150–350X109/L). Chemistries were within reference range, except for an alkaline phosphatase level of 136 U/L (reference range, 38–126 U/L). Biopsy of a forearm skin lesion showed an unremarkable epidermal layer overlying a dermis without vasculitis but with a mild increase in perivascular and focally interstitial mononuclear cells staining with mast cell tryptase and CD117. Serum tryptase level was greater than 200 ng/mL (reference,

References

 

  1. Mekori YA, Metcalfe DD. Mast cell-T cell interactions. J Allergy Clin Immunol. 1999;104(3, pt 1):517-523.
  2. Weller K, Foitzik K, Paus R, et al. Mast cells are required for normal healing of skin wounds in mice. FASEB J. 2006;20:2366-2368. Epub September 11, 2006.
  3. Nienartowicz A, Sobaniec-Lotowska ME, Jarocka-Cyrta E, et al. Mast cells in neoangiogenesis. Med Sci Monit. 2006;12:RA53-56. Epub February 23, 2006.
  4. Valent P, Akin C, Sperr WR, et al. Mastocytosis: pathology, genetics, and current options for therapy. Leuk Lymphoma. 2005;46:35-48.
  5. The World Health Organization. Mastocytosis. In: Jaffe ES, Harris NL, Stein H, et al, eds. WHO Classification of Tumours: Pathology and Genetics of Tumours of Haematopoetic and Lymphoid Tissues. Vol 3. IARC Press: Lyon, France; 2001:293-302.
  6. Wolff K, Komar M, Petzelbauer P. Clinical and histopathological aspects of cutaneous mastocytosis. Leuk Res. 2001;25:519-528.
  7. Valent P, Akin C, Sperr WR, et al. Mast cell proliferative disorders: current view on variants recognized by the World Health Organization. Hematol Oncol Clin North Am. 2003;17:1227-1241.
  8. Stankovic K, Sarrot-Reynauld F, Puget M, et al. Systemic mastocytosis: predictable factors of poor prognosis present at the onset of the disease. Eur J Intern Med. 2005;16:387-390.
  9. Chott A, Guenther P, Huebner A, et al. Morphologic and immunophenotypic properties of neoplastic cells in a case of mast cell sarcoma. Am J Surg Pathol. 2003;27:1013-1019.
  10. Schernthaner GH, Jordan JH, Ghannadan M, et al. Expression, epitope analysis, and functional role of the LFA-2 antigen detectable on neoplastic mast cells. Blood. 2001;98:3784-3792.
  11. Metcalfe DD. Regulation of normal and neoplastic human mast cell development in mastocytosis. Trans Am Clin Climatol Assoc. 2005;116:185-203.
  12. Mickys U, Barakauskiene A, Wolf-Peeters D, et al. Aggressive systemic mastocytosis complicated by protein-losing enteropathy. Dig Liver Dis. 2007;39:693-697. Epub July 14, 2006.
  13. Jensen RT. Gastrointestinal abnormalities and involvement in systemic mastocytosis. Hematol Oncol Clin North Am. 2000;14:579-623.
  14. Horny HP, Kaiserling E, Campbell M, et al. Liver findings in generalized mastocytosis. a clinicopathologic study. Cancer. 1989;63:532-538.
  15. Webb TA, Li CY, Yam LT. Systemic mast cell disease: a clinical and hematopathologic study of 26 cases. Cancer. 1982;49:927-938.
  16. Chen CC, Andrich MP, Mican JM, et al. A retrospective analysis of bone scan abnormalities in mastocytosis: correlation with disease category and prognosis. J Nucl Med. 1994;35:1471-1475.
  17. van Toorenenbergen AW, Oranje AP. Comparison of serum tryptase and urine N-methylhistamine in patients with suspected mastocytosis. Clin Chim Acta. 2005;359(1-2):72-77.
  18. Horan RF, Sheffer AL, Austen KF. Cromolyn sodium in the management of systemic mastocytosis. J Allergy Clin Immunol. 1990;85: 852-855.
  19. Friedman B, Darling G, Norton J, et al. Splenectomy in the management of systemic mast cell disease. Surgery. 1990;107:94-100.
  20. Quintas-Cardama A, Aribi A, Cortes J, et al. Novel approaches in the treatment of systemic mastocytosis. Cancer. 2006;107:1429-1439.
  21. Casassus P, Caillat-Vigneron N, Martin A, et al. Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients. Br J Haematol. 2002;119:1090-1097.
  22. Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, et al. Cladribine therapy for systemic mastocytosis. Blood. 2003;102:4270-4276. Epub August 21, 2003.
  23. Droogendijk HJ, Kluin-Nelemans HJ, van Doormaal JJ, et al. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial. C
Article PDF
Author and Disclosure Information

 

This article has been peer reviewed and approved by Michael Fisher, MD, Professor of Medicine, Albert Einstein College of Medicine. Review date: December 2008.

Drs. Bunimovich, Grassi, and Baer report no conflict of interest. The authors discuss off-label use of dasatinib for systemic mastocytosis. Dr. Fisher reports no conflict of interest. The staff of CCME of Albert Einstein College of Medicine and Cutis® have no conflicts of interest with commercial interest related directly or indirectly to this educational activity. Dr. Bunimovich is a resident, Department of Dermatology, State University of New York, Buffalo School of Medicine. Dr. Grassi is Assistant Clinical Professor, Department of Dermatology, and Dr. Baer was Professor, Department of Medicine, both from Roswell Park Cancer Institute, Buffalo. Dr. Baer currently is Professor of Medicine, Greenbaum Cancer Center, University of Maryland, Baltimore.

Olga Bunimovich, MD; Marcelle Grassi, MD; Maria R. Baer, MD

Issue
Cutis - 83(1)
Publications
Page Number
29-36
Author and Disclosure Information

 

This article has been peer reviewed and approved by Michael Fisher, MD, Professor of Medicine, Albert Einstein College of Medicine. Review date: December 2008.

Drs. Bunimovich, Grassi, and Baer report no conflict of interest. The authors discuss off-label use of dasatinib for systemic mastocytosis. Dr. Fisher reports no conflict of interest. The staff of CCME of Albert Einstein College of Medicine and Cutis® have no conflicts of interest with commercial interest related directly or indirectly to this educational activity. Dr. Bunimovich is a resident, Department of Dermatology, State University of New York, Buffalo School of Medicine. Dr. Grassi is Assistant Clinical Professor, Department of Dermatology, and Dr. Baer was Professor, Department of Medicine, both from Roswell Park Cancer Institute, Buffalo. Dr. Baer currently is Professor of Medicine, Greenbaum Cancer Center, University of Maryland, Baltimore.

Olga Bunimovich, MD; Marcelle Grassi, MD; Maria R. Baer, MD

Author and Disclosure Information

 

This article has been peer reviewed and approved by Michael Fisher, MD, Professor of Medicine, Albert Einstein College of Medicine. Review date: December 2008.

Drs. Bunimovich, Grassi, and Baer report no conflict of interest. The authors discuss off-label use of dasatinib for systemic mastocytosis. Dr. Fisher reports no conflict of interest. The staff of CCME of Albert Einstein College of Medicine and Cutis® have no conflicts of interest with commercial interest related directly or indirectly to this educational activity. Dr. Bunimovich is a resident, Department of Dermatology, State University of New York, Buffalo School of Medicine. Dr. Grassi is Assistant Clinical Professor, Department of Dermatology, and Dr. Baer was Professor, Department of Medicine, both from Roswell Park Cancer Institute, Buffalo. Dr. Baer currently is Professor of Medicine, Greenbaum Cancer Center, University of Maryland, Baltimore.

Olga Bunimovich, MD; Marcelle Grassi, MD; Maria R. Baer, MD

Article PDF
Article PDF


Case Report
A 46-year-old woman presented with a rash that had been present for more than 20 years but had progressed over the past 6 years and was associated with pruritus, burning, and blistering precipitated by temperature changes or anxiety. In addition, she had watery diarrhea for 5 years and also had been found to have osteopenia. She was a healthy-appearing woman with prominent facial erythema. Vital signs were normal. Skin examination revealed facial telangiectases as well as erythema and 2- to 4-mm reddish brown papules and macules on the extensor surfaces of the arms and thighs, chest, abdomen, and back, coalescing into plaques on the thighs (Figure). She had bilateral axillary lymphadenopathy. Liver and spleen were not palpable. Her hemoglobin level was 12.7 g/dL (reference range, 14.0–17.5 g/dL); white blood cell count was 5.2X109/L (reference range, 4.5–11.0X109/L) with 63 neutrophils, 36 lymphocytes, and 1 monocyte; and platelet count was 301X109/L (reference range, 150–350X109/L). Chemistries were within reference range, except for an alkaline phosphatase level of 136 U/L (reference range, 38–126 U/L). Biopsy of a forearm skin lesion showed an unremarkable epidermal layer overlying a dermis without vasculitis but with a mild increase in perivascular and focally interstitial mononuclear cells staining with mast cell tryptase and CD117. Serum tryptase level was greater than 200 ng/mL (reference,


Case Report
A 46-year-old woman presented with a rash that had been present for more than 20 years but had progressed over the past 6 years and was associated with pruritus, burning, and blistering precipitated by temperature changes or anxiety. In addition, she had watery diarrhea for 5 years and also had been found to have osteopenia. She was a healthy-appearing woman with prominent facial erythema. Vital signs were normal. Skin examination revealed facial telangiectases as well as erythema and 2- to 4-mm reddish brown papules and macules on the extensor surfaces of the arms and thighs, chest, abdomen, and back, coalescing into plaques on the thighs (Figure). She had bilateral axillary lymphadenopathy. Liver and spleen were not palpable. Her hemoglobin level was 12.7 g/dL (reference range, 14.0–17.5 g/dL); white blood cell count was 5.2X109/L (reference range, 4.5–11.0X109/L) with 63 neutrophils, 36 lymphocytes, and 1 monocyte; and platelet count was 301X109/L (reference range, 150–350X109/L). Chemistries were within reference range, except for an alkaline phosphatase level of 136 U/L (reference range, 38–126 U/L). Biopsy of a forearm skin lesion showed an unremarkable epidermal layer overlying a dermis without vasculitis but with a mild increase in perivascular and focally interstitial mononuclear cells staining with mast cell tryptase and CD117. Serum tryptase level was greater than 200 ng/mL (reference,

References

 

  1. Mekori YA, Metcalfe DD. Mast cell-T cell interactions. J Allergy Clin Immunol. 1999;104(3, pt 1):517-523.
  2. Weller K, Foitzik K, Paus R, et al. Mast cells are required for normal healing of skin wounds in mice. FASEB J. 2006;20:2366-2368. Epub September 11, 2006.
  3. Nienartowicz A, Sobaniec-Lotowska ME, Jarocka-Cyrta E, et al. Mast cells in neoangiogenesis. Med Sci Monit. 2006;12:RA53-56. Epub February 23, 2006.
  4. Valent P, Akin C, Sperr WR, et al. Mastocytosis: pathology, genetics, and current options for therapy. Leuk Lymphoma. 2005;46:35-48.
  5. The World Health Organization. Mastocytosis. In: Jaffe ES, Harris NL, Stein H, et al, eds. WHO Classification of Tumours: Pathology and Genetics of Tumours of Haematopoetic and Lymphoid Tissues. Vol 3. IARC Press: Lyon, France; 2001:293-302.
  6. Wolff K, Komar M, Petzelbauer P. Clinical and histopathological aspects of cutaneous mastocytosis. Leuk Res. 2001;25:519-528.
  7. Valent P, Akin C, Sperr WR, et al. Mast cell proliferative disorders: current view on variants recognized by the World Health Organization. Hematol Oncol Clin North Am. 2003;17:1227-1241.
  8. Stankovic K, Sarrot-Reynauld F, Puget M, et al. Systemic mastocytosis: predictable factors of poor prognosis present at the onset of the disease. Eur J Intern Med. 2005;16:387-390.
  9. Chott A, Guenther P, Huebner A, et al. Morphologic and immunophenotypic properties of neoplastic cells in a case of mast cell sarcoma. Am J Surg Pathol. 2003;27:1013-1019.
  10. Schernthaner GH, Jordan JH, Ghannadan M, et al. Expression, epitope analysis, and functional role of the LFA-2 antigen detectable on neoplastic mast cells. Blood. 2001;98:3784-3792.
  11. Metcalfe DD. Regulation of normal and neoplastic human mast cell development in mastocytosis. Trans Am Clin Climatol Assoc. 2005;116:185-203.
  12. Mickys U, Barakauskiene A, Wolf-Peeters D, et al. Aggressive systemic mastocytosis complicated by protein-losing enteropathy. Dig Liver Dis. 2007;39:693-697. Epub July 14, 2006.
  13. Jensen RT. Gastrointestinal abnormalities and involvement in systemic mastocytosis. Hematol Oncol Clin North Am. 2000;14:579-623.
  14. Horny HP, Kaiserling E, Campbell M, et al. Liver findings in generalized mastocytosis. a clinicopathologic study. Cancer. 1989;63:532-538.
  15. Webb TA, Li CY, Yam LT. Systemic mast cell disease: a clinical and hematopathologic study of 26 cases. Cancer. 1982;49:927-938.
  16. Chen CC, Andrich MP, Mican JM, et al. A retrospective analysis of bone scan abnormalities in mastocytosis: correlation with disease category and prognosis. J Nucl Med. 1994;35:1471-1475.
  17. van Toorenenbergen AW, Oranje AP. Comparison of serum tryptase and urine N-methylhistamine in patients with suspected mastocytosis. Clin Chim Acta. 2005;359(1-2):72-77.
  18. Horan RF, Sheffer AL, Austen KF. Cromolyn sodium in the management of systemic mastocytosis. J Allergy Clin Immunol. 1990;85: 852-855.
  19. Friedman B, Darling G, Norton J, et al. Splenectomy in the management of systemic mast cell disease. Surgery. 1990;107:94-100.
  20. Quintas-Cardama A, Aribi A, Cortes J, et al. Novel approaches in the treatment of systemic mastocytosis. Cancer. 2006;107:1429-1439.
  21. Casassus P, Caillat-Vigneron N, Martin A, et al. Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients. Br J Haematol. 2002;119:1090-1097.
  22. Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, et al. Cladribine therapy for systemic mastocytosis. Blood. 2003;102:4270-4276. Epub August 21, 2003.
  23. Droogendijk HJ, Kluin-Nelemans HJ, van Doormaal JJ, et al. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial. C
References

 

  1. Mekori YA, Metcalfe DD. Mast cell-T cell interactions. J Allergy Clin Immunol. 1999;104(3, pt 1):517-523.
  2. Weller K, Foitzik K, Paus R, et al. Mast cells are required for normal healing of skin wounds in mice. FASEB J. 2006;20:2366-2368. Epub September 11, 2006.
  3. Nienartowicz A, Sobaniec-Lotowska ME, Jarocka-Cyrta E, et al. Mast cells in neoangiogenesis. Med Sci Monit. 2006;12:RA53-56. Epub February 23, 2006.
  4. Valent P, Akin C, Sperr WR, et al. Mastocytosis: pathology, genetics, and current options for therapy. Leuk Lymphoma. 2005;46:35-48.
  5. The World Health Organization. Mastocytosis. In: Jaffe ES, Harris NL, Stein H, et al, eds. WHO Classification of Tumours: Pathology and Genetics of Tumours of Haematopoetic and Lymphoid Tissues. Vol 3. IARC Press: Lyon, France; 2001:293-302.
  6. Wolff K, Komar M, Petzelbauer P. Clinical and histopathological aspects of cutaneous mastocytosis. Leuk Res. 2001;25:519-528.
  7. Valent P, Akin C, Sperr WR, et al. Mast cell proliferative disorders: current view on variants recognized by the World Health Organization. Hematol Oncol Clin North Am. 2003;17:1227-1241.
  8. Stankovic K, Sarrot-Reynauld F, Puget M, et al. Systemic mastocytosis: predictable factors of poor prognosis present at the onset of the disease. Eur J Intern Med. 2005;16:387-390.
  9. Chott A, Guenther P, Huebner A, et al. Morphologic and immunophenotypic properties of neoplastic cells in a case of mast cell sarcoma. Am J Surg Pathol. 2003;27:1013-1019.
  10. Schernthaner GH, Jordan JH, Ghannadan M, et al. Expression, epitope analysis, and functional role of the LFA-2 antigen detectable on neoplastic mast cells. Blood. 2001;98:3784-3792.
  11. Metcalfe DD. Regulation of normal and neoplastic human mast cell development in mastocytosis. Trans Am Clin Climatol Assoc. 2005;116:185-203.
  12. Mickys U, Barakauskiene A, Wolf-Peeters D, et al. Aggressive systemic mastocytosis complicated by protein-losing enteropathy. Dig Liver Dis. 2007;39:693-697. Epub July 14, 2006.
  13. Jensen RT. Gastrointestinal abnormalities and involvement in systemic mastocytosis. Hematol Oncol Clin North Am. 2000;14:579-623.
  14. Horny HP, Kaiserling E, Campbell M, et al. Liver findings in generalized mastocytosis. a clinicopathologic study. Cancer. 1989;63:532-538.
  15. Webb TA, Li CY, Yam LT. Systemic mast cell disease: a clinical and hematopathologic study of 26 cases. Cancer. 1982;49:927-938.
  16. Chen CC, Andrich MP, Mican JM, et al. A retrospective analysis of bone scan abnormalities in mastocytosis: correlation with disease category and prognosis. J Nucl Med. 1994;35:1471-1475.
  17. van Toorenenbergen AW, Oranje AP. Comparison of serum tryptase and urine N-methylhistamine in patients with suspected mastocytosis. Clin Chim Acta. 2005;359(1-2):72-77.
  18. Horan RF, Sheffer AL, Austen KF. Cromolyn sodium in the management of systemic mastocytosis. J Allergy Clin Immunol. 1990;85: 852-855.
  19. Friedman B, Darling G, Norton J, et al. Splenectomy in the management of systemic mast cell disease. Surgery. 1990;107:94-100.
  20. Quintas-Cardama A, Aribi A, Cortes J, et al. Novel approaches in the treatment of systemic mastocytosis. Cancer. 2006;107:1429-1439.
  21. Casassus P, Caillat-Vigneron N, Martin A, et al. Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients. Br J Haematol. 2002;119:1090-1097.
  22. Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, et al. Cladribine therapy for systemic mastocytosis. Blood. 2003;102:4270-4276. Epub August 21, 2003.
  23. Droogendijk HJ, Kluin-Nelemans HJ, van Doormaal JJ, et al. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial. C
Issue
Cutis - 83(1)
Issue
Cutis - 83(1)
Page Number
29-36
Page Number
29-36
Publications
Publications
Article Type
Display Headline
Systemic Mastocytosis: Classification, Pathogenesis, Diagnosis, and Treatment
Display Headline
Systemic Mastocytosis: Classification, Pathogenesis, Diagnosis, and Treatment
Disallow All Ads
Article PDF Media

Glomangioma: A Case Report and Review of the Literature

Article Type
Changed
Display Headline
Glomangioma: A Case Report and Review of the Literature


Case Report
A 69-year-old man with a medical history of psoriasis and hypertension presented with an incidental finding of multiple asymptomatic, noncompressible, blue lesions over his arms, chest, and back. The lesions were present since childhood and had never been subject to a workup. He had no history of gastrointestinal bleeding and no known family history of similar lesions. His medications included amlodipine besylate, efalizumab, and valsartan. Physical examination revealed multiple nontender, blue, subcutaneous nodules that were 1 to 2 cm in diameter and located on the bilateral arms, chest, and back (Figure 1). A punch biopsy was performed from the chest lesions. Histopathologic examination revealed dilated vascular channels (Figure 2) that were positive for endothelial factor VIII and CD34 and surrounded by glomus cells positive for smooth muscle actin (Figure 3). The diagnosis of glomangioma was made and no further treatment was indicated.

back to top


Comment
Glomangiomas are benign localized tumors of the skin characterized by abnormal, smooth muscle–like glomus cells.1 In 1924, Masson2 described the neuromyoarterial glomus, which he later renamed the neurovascular glomus, and its tumors. The term glomangioma was coined by Bailey3 in 1935 and is currently applied to lesions with a wide vascular lumen, which are most commonly found in patients with multiple tumors.4 Glomus tumors arise from modified smooth muscle cells normally found in specialized arteriovenous shunts present in acral sites, especially the fingertips. This location reflects their function, as the arteriovenous anastomoses of these areas, also known as the Sucquet-Hoyer canals, are involved in temperature regulation. Sucquet-Hoyer canals are lined with endothelial cells, contain several layers of glomus cells in their walls, and connect afferent arterioles to efferent venules.5 Glomus tumors are thought to be hamartomas6 and account for 1% to 2% of all soft tissue tumors.5 There are 2 forms of glomus tumors, with the more common solitary variant accounting for 90% of cases and a more rare multiple variant, termed glomangioma, accounting for 10% of cases.7 The tumors of the solitary variant are small, painful, purple nodules with predilection for acral areas of the extremities, especially the nail beds of the fingers and toes.8 Aching pain, well-localized tenderness, and temperature sensitivity are the characteristic triad of signs and symptoms.5 They typically are less than 1 cm in diameter.8 In contrast, multiple glomus tumors are characterized as glomangiomas because of the angiomatous appearance of the lesions. Glomangiomas often appear during childhood as small bluish nodules situated deep in the dermis, widely scattered over the skin surface. They are rarely subungual and are less likely to be painful.8 Glomangiomas have a predilection for the upper extremities and occasionally are found on the lower extremities, head, and back. They may be slightly larger and less well-circumscribed than solitary glomus tumors.5 An autosomal dominant inheritance pattern has been described for glomus tumors, with some types being mapped to band 11q23.6 Familial cases have been reported with incomplete penetrance and variable expression.7 Glomangiomas have a male predominance, while females more frequently (in 70% of cases) are found to have solitary glomus tumors.5 Histopathologically, glomus tumors contain dilated vascular channels surrounded by glomus cells. The glomus cells are monomorphic round or polygonal cells with plump nuclei and scant eosinophilic cytoplasm. They are positive for smooth muscle actin, while vascular endothelium is positive for factor VIII and CD34.9 Choosing the appropriate treatment regimen for glomus tumors and glomangiomas should be individualized to the patient and guided by the clinical presentation. Treatment is not always indicated, particularly in asymptomatic cases of glomangioma. Surgical intervention, when needed, typically is excision with primary closure. Laser treatment, electromagnetic radiation, and sclerotherapy also have been used.5 Blue Rubber Bleb Nevus Syndrome—It is important to distinguish glomangioma from blue rubber bleb nevus syndrome (BRBNS), which is associated with venous malformations on both the skin and gastrointestinal tract. The BRBNS venous malformations of the gastrointestinal tract can be associated with clinically significant gastrointestinal bleeding.10 Lesions of BRBNS can be macular, papular, or nodular, and usually are multiple, varying in diameter from a few millimeters to several centimeters. The cutaneous lesions usually are asymptomatic and the overlying skin may show increased sweating. These lesions may appear at birth or in early childhood, and they tend to increase in size and frequency with age. Although they may occur anywhere, they are principally located on the upper limbs, trunk, and perineum. Acral lesions are unusual and the lesions have no evidence of malignant change.11 Cutaneous lesions of BRBNS are blue, soft, and nipplelike, easily compressing and refilling slowly.12 On the other hand, glomangiomas are noted for a distinct raised, often hyperkeratotic, cobblestonelike appearance, and could not be completely emptied by compression.13 Glomangiomas generally do not extend into deep structures.14 Histologically, glomangiomas contain clusters of dilated vascular channels lined by a thin layer of endothelial cells in the dermis or subcutaneous fat. The walls are a fibrous stroma, occasionally containing smooth muscle.12 Dilated vascular channels lined by endothelial cells are characteristic of both diseases. Therefore, biopsy results confirming the presence of glomus cells lining the dilated vascular channels characterize glomangiomas.10 back to top


References

  1. Parsi K, Kossard S. Multiple hereditary glomangiomas: successful treatment with sclerotherapy. Aust J Dermatol. 2002;43:43-47.
  2. Masson P. Le glomus neuromyo-artériel des régions tactiles et ses tumeurs. Lyon Chir. 1924;21:257-280.
  3. Bailey OT. The cutaneous glomus and its tumors—glomangiomas. Am J Pathol. 1935;11:915-936.
  4. Monteagudo C, Carda C, Llombart-Bosch A, et al. Multiple glomangiomyoma versus glomangioma: conceptual and ultrastructural observations. Am J Dermatopathol. 2000;22:371-373.
  5. Myers RS, Lo AK, Pawel BR. The glomangioma in the differential diagnosis of vascular malformations. Ann Plast Surg. 2006;57:443-446.
  6. Blume-Peytavi U, Adler YD, Geilen CC, et al. Multiple familial cutaneous glomangioma: a pedigree of 4 generations and critical analysis of histologic and genetic differences of glomus tumors. J Am Acad Dermatol. 2000;42:633-639.
  7. Chatterjee JS, Youssef AHK, Brown RM, et al. Congenital nodular multiple glomangioma: a case report. J Clin Pathol. 2005;58:102-103.
  8. Requena L, Galvan C, Sanchez Yus E, et al. Solitary plaque-like telangiectatic glomangioma. Br J Dermatol. 1998;139:902-905.
  9. Abou Jaoude JF, Roula Farah A, Sargi Z, et al. Glomus tumors: report on eleven cases and a review of the literature. Chir Main. 2000;19:243-252.
  10. Lu R, Krathen RA, Sanchez RL, et al. Multiple glomangiomas: potential for confusion with blue rubber bleb nevus syndrome. J Am Acad Dermatol. 2005;52:731-732.
  11. Moodley M, Ramdial P. Blue rubber bleb nevus syndrome: case report and review of the literature. Pediatrics. 1993;92:160-162.
  12. Nahm WK, Moise S, Eichenfield LF, et al. Venous malformations in blue rubber bleb nevus syndrome: variable onset of presentation. J Am Acad Dermatol. 2004;50:101-106.
  13. Boon LM, Mulliken JB, Enjolras O, et al. Glomuvenous malformation (glomangioma) and venous malformation: distinct clinicopathologic and genetic entities. Arch Dermatol. 2004;140:971-976.
  14. Vercellino N, Nozza P, Oddone M, et al. Large plaque-like glomuvenous malformation (glomangioma) simulating venous malformation. Clin Exp Dermatol. 2006;31:538-541.
Article PDF
Author and Disclosure Information

This article has been peer reviewed and approved by Michael Fisher, MD, Professor of Medicine, Albert Einstein College of Medicine. Review date: December 2008.

Drs. Schopp and Sra report no conflict of interest. Dr. Wilkerson is on the speakers bureau for Abbott Laboratories and Genentech, Inc, and has received grant/research support from Amgen Inc; Galderma Laboratories, LP; and GlaxoSmithKline, but these relationships are not relevant to this article. The authors report no discussion of off-label use. Dr. Fisher reports no conflict of interest. The staff of CCME of Albert Einstein College of Medicine and Cutis® have no conflicts of interest with commercial interest related directly or indirectly to this educational activity. Dr. Schopp was a medical student, Dr. Sra was a resident, and Dr. Wilkerson is Associate Professor, Department of Dermatology, all from University of Texas Medical Branch, Galveston. Dr. Schopp currently is a transitional intern, University of Texas Medical Branch, Austin, and Dr. Sra currently is in private practice, Dermatological Association of Texas, Webster.

Jennifer G. Schopp, MD; Karan K. Sra, MD; Michael G. Wilkerson, MD

Issue
Cutis - 83(1)
Publications
Topics
Page Number
24-27
Author and Disclosure Information

This article has been peer reviewed and approved by Michael Fisher, MD, Professor of Medicine, Albert Einstein College of Medicine. Review date: December 2008.

Drs. Schopp and Sra report no conflict of interest. Dr. Wilkerson is on the speakers bureau for Abbott Laboratories and Genentech, Inc, and has received grant/research support from Amgen Inc; Galderma Laboratories, LP; and GlaxoSmithKline, but these relationships are not relevant to this article. The authors report no discussion of off-label use. Dr. Fisher reports no conflict of interest. The staff of CCME of Albert Einstein College of Medicine and Cutis® have no conflicts of interest with commercial interest related directly or indirectly to this educational activity. Dr. Schopp was a medical student, Dr. Sra was a resident, and Dr. Wilkerson is Associate Professor, Department of Dermatology, all from University of Texas Medical Branch, Galveston. Dr. Schopp currently is a transitional intern, University of Texas Medical Branch, Austin, and Dr. Sra currently is in private practice, Dermatological Association of Texas, Webster.

Jennifer G. Schopp, MD; Karan K. Sra, MD; Michael G. Wilkerson, MD

Author and Disclosure Information

This article has been peer reviewed and approved by Michael Fisher, MD, Professor of Medicine, Albert Einstein College of Medicine. Review date: December 2008.

Drs. Schopp and Sra report no conflict of interest. Dr. Wilkerson is on the speakers bureau for Abbott Laboratories and Genentech, Inc, and has received grant/research support from Amgen Inc; Galderma Laboratories, LP; and GlaxoSmithKline, but these relationships are not relevant to this article. The authors report no discussion of off-label use. Dr. Fisher reports no conflict of interest. The staff of CCME of Albert Einstein College of Medicine and Cutis® have no conflicts of interest with commercial interest related directly or indirectly to this educational activity. Dr. Schopp was a medical student, Dr. Sra was a resident, and Dr. Wilkerson is Associate Professor, Department of Dermatology, all from University of Texas Medical Branch, Galveston. Dr. Schopp currently is a transitional intern, University of Texas Medical Branch, Austin, and Dr. Sra currently is in private practice, Dermatological Association of Texas, Webster.

Jennifer G. Schopp, MD; Karan K. Sra, MD; Michael G. Wilkerson, MD

Article PDF
Article PDF


Case Report
A 69-year-old man with a medical history of psoriasis and hypertension presented with an incidental finding of multiple asymptomatic, noncompressible, blue lesions over his arms, chest, and back. The lesions were present since childhood and had never been subject to a workup. He had no history of gastrointestinal bleeding and no known family history of similar lesions. His medications included amlodipine besylate, efalizumab, and valsartan. Physical examination revealed multiple nontender, blue, subcutaneous nodules that were 1 to 2 cm in diameter and located on the bilateral arms, chest, and back (Figure 1). A punch biopsy was performed from the chest lesions. Histopathologic examination revealed dilated vascular channels (Figure 2) that were positive for endothelial factor VIII and CD34 and surrounded by glomus cells positive for smooth muscle actin (Figure 3). The diagnosis of glomangioma was made and no further treatment was indicated.

back to top


Comment
Glomangiomas are benign localized tumors of the skin characterized by abnormal, smooth muscle–like glomus cells.1 In 1924, Masson2 described the neuromyoarterial glomus, which he later renamed the neurovascular glomus, and its tumors. The term glomangioma was coined by Bailey3 in 1935 and is currently applied to lesions with a wide vascular lumen, which are most commonly found in patients with multiple tumors.4 Glomus tumors arise from modified smooth muscle cells normally found in specialized arteriovenous shunts present in acral sites, especially the fingertips. This location reflects their function, as the arteriovenous anastomoses of these areas, also known as the Sucquet-Hoyer canals, are involved in temperature regulation. Sucquet-Hoyer canals are lined with endothelial cells, contain several layers of glomus cells in their walls, and connect afferent arterioles to efferent venules.5 Glomus tumors are thought to be hamartomas6 and account for 1% to 2% of all soft tissue tumors.5 There are 2 forms of glomus tumors, with the more common solitary variant accounting for 90% of cases and a more rare multiple variant, termed glomangioma, accounting for 10% of cases.7 The tumors of the solitary variant are small, painful, purple nodules with predilection for acral areas of the extremities, especially the nail beds of the fingers and toes.8 Aching pain, well-localized tenderness, and temperature sensitivity are the characteristic triad of signs and symptoms.5 They typically are less than 1 cm in diameter.8 In contrast, multiple glomus tumors are characterized as glomangiomas because of the angiomatous appearance of the lesions. Glomangiomas often appear during childhood as small bluish nodules situated deep in the dermis, widely scattered over the skin surface. They are rarely subungual and are less likely to be painful.8 Glomangiomas have a predilection for the upper extremities and occasionally are found on the lower extremities, head, and back. They may be slightly larger and less well-circumscribed than solitary glomus tumors.5 An autosomal dominant inheritance pattern has been described for glomus tumors, with some types being mapped to band 11q23.6 Familial cases have been reported with incomplete penetrance and variable expression.7 Glomangiomas have a male predominance, while females more frequently (in 70% of cases) are found to have solitary glomus tumors.5 Histopathologically, glomus tumors contain dilated vascular channels surrounded by glomus cells. The glomus cells are monomorphic round or polygonal cells with plump nuclei and scant eosinophilic cytoplasm. They are positive for smooth muscle actin, while vascular endothelium is positive for factor VIII and CD34.9 Choosing the appropriate treatment regimen for glomus tumors and glomangiomas should be individualized to the patient and guided by the clinical presentation. Treatment is not always indicated, particularly in asymptomatic cases of glomangioma. Surgical intervention, when needed, typically is excision with primary closure. Laser treatment, electromagnetic radiation, and sclerotherapy also have been used.5 Blue Rubber Bleb Nevus Syndrome—It is important to distinguish glomangioma from blue rubber bleb nevus syndrome (BRBNS), which is associated with venous malformations on both the skin and gastrointestinal tract. The BRBNS venous malformations of the gastrointestinal tract can be associated with clinically significant gastrointestinal bleeding.10 Lesions of BRBNS can be macular, papular, or nodular, and usually are multiple, varying in diameter from a few millimeters to several centimeters. The cutaneous lesions usually are asymptomatic and the overlying skin may show increased sweating. These lesions may appear at birth or in early childhood, and they tend to increase in size and frequency with age. Although they may occur anywhere, they are principally located on the upper limbs, trunk, and perineum. Acral lesions are unusual and the lesions have no evidence of malignant change.11 Cutaneous lesions of BRBNS are blue, soft, and nipplelike, easily compressing and refilling slowly.12 On the other hand, glomangiomas are noted for a distinct raised, often hyperkeratotic, cobblestonelike appearance, and could not be completely emptied by compression.13 Glomangiomas generally do not extend into deep structures.14 Histologically, glomangiomas contain clusters of dilated vascular channels lined by a thin layer of endothelial cells in the dermis or subcutaneous fat. The walls are a fibrous stroma, occasionally containing smooth muscle.12 Dilated vascular channels lined by endothelial cells are characteristic of both diseases. Therefore, biopsy results confirming the presence of glomus cells lining the dilated vascular channels characterize glomangiomas.10 back to top



Case Report
A 69-year-old man with a medical history of psoriasis and hypertension presented with an incidental finding of multiple asymptomatic, noncompressible, blue lesions over his arms, chest, and back. The lesions were present since childhood and had never been subject to a workup. He had no history of gastrointestinal bleeding and no known family history of similar lesions. His medications included amlodipine besylate, efalizumab, and valsartan. Physical examination revealed multiple nontender, blue, subcutaneous nodules that were 1 to 2 cm in diameter and located on the bilateral arms, chest, and back (Figure 1). A punch biopsy was performed from the chest lesions. Histopathologic examination revealed dilated vascular channels (Figure 2) that were positive for endothelial factor VIII and CD34 and surrounded by glomus cells positive for smooth muscle actin (Figure 3). The diagnosis of glomangioma was made and no further treatment was indicated.

back to top


Comment
Glomangiomas are benign localized tumors of the skin characterized by abnormal, smooth muscle–like glomus cells.1 In 1924, Masson2 described the neuromyoarterial glomus, which he later renamed the neurovascular glomus, and its tumors. The term glomangioma was coined by Bailey3 in 1935 and is currently applied to lesions with a wide vascular lumen, which are most commonly found in patients with multiple tumors.4 Glomus tumors arise from modified smooth muscle cells normally found in specialized arteriovenous shunts present in acral sites, especially the fingertips. This location reflects their function, as the arteriovenous anastomoses of these areas, also known as the Sucquet-Hoyer canals, are involved in temperature regulation. Sucquet-Hoyer canals are lined with endothelial cells, contain several layers of glomus cells in their walls, and connect afferent arterioles to efferent venules.5 Glomus tumors are thought to be hamartomas6 and account for 1% to 2% of all soft tissue tumors.5 There are 2 forms of glomus tumors, with the more common solitary variant accounting for 90% of cases and a more rare multiple variant, termed glomangioma, accounting for 10% of cases.7 The tumors of the solitary variant are small, painful, purple nodules with predilection for acral areas of the extremities, especially the nail beds of the fingers and toes.8 Aching pain, well-localized tenderness, and temperature sensitivity are the characteristic triad of signs and symptoms.5 They typically are less than 1 cm in diameter.8 In contrast, multiple glomus tumors are characterized as glomangiomas because of the angiomatous appearance of the lesions. Glomangiomas often appear during childhood as small bluish nodules situated deep in the dermis, widely scattered over the skin surface. They are rarely subungual and are less likely to be painful.8 Glomangiomas have a predilection for the upper extremities and occasionally are found on the lower extremities, head, and back. They may be slightly larger and less well-circumscribed than solitary glomus tumors.5 An autosomal dominant inheritance pattern has been described for glomus tumors, with some types being mapped to band 11q23.6 Familial cases have been reported with incomplete penetrance and variable expression.7 Glomangiomas have a male predominance, while females more frequently (in 70% of cases) are found to have solitary glomus tumors.5 Histopathologically, glomus tumors contain dilated vascular channels surrounded by glomus cells. The glomus cells are monomorphic round or polygonal cells with plump nuclei and scant eosinophilic cytoplasm. They are positive for smooth muscle actin, while vascular endothelium is positive for factor VIII and CD34.9 Choosing the appropriate treatment regimen for glomus tumors and glomangiomas should be individualized to the patient and guided by the clinical presentation. Treatment is not always indicated, particularly in asymptomatic cases of glomangioma. Surgical intervention, when needed, typically is excision with primary closure. Laser treatment, electromagnetic radiation, and sclerotherapy also have been used.5 Blue Rubber Bleb Nevus Syndrome—It is important to distinguish glomangioma from blue rubber bleb nevus syndrome (BRBNS), which is associated with venous malformations on both the skin and gastrointestinal tract. The BRBNS venous malformations of the gastrointestinal tract can be associated with clinically significant gastrointestinal bleeding.10 Lesions of BRBNS can be macular, papular, or nodular, and usually are multiple, varying in diameter from a few millimeters to several centimeters. The cutaneous lesions usually are asymptomatic and the overlying skin may show increased sweating. These lesions may appear at birth or in early childhood, and they tend to increase in size and frequency with age. Although they may occur anywhere, they are principally located on the upper limbs, trunk, and perineum. Acral lesions are unusual and the lesions have no evidence of malignant change.11 Cutaneous lesions of BRBNS are blue, soft, and nipplelike, easily compressing and refilling slowly.12 On the other hand, glomangiomas are noted for a distinct raised, often hyperkeratotic, cobblestonelike appearance, and could not be completely emptied by compression.13 Glomangiomas generally do not extend into deep structures.14 Histologically, glomangiomas contain clusters of dilated vascular channels lined by a thin layer of endothelial cells in the dermis or subcutaneous fat. The walls are a fibrous stroma, occasionally containing smooth muscle.12 Dilated vascular channels lined by endothelial cells are characteristic of both diseases. Therefore, biopsy results confirming the presence of glomus cells lining the dilated vascular channels characterize glomangiomas.10 back to top


References

  1. Parsi K, Kossard S. Multiple hereditary glomangiomas: successful treatment with sclerotherapy. Aust J Dermatol. 2002;43:43-47.
  2. Masson P. Le glomus neuromyo-artériel des régions tactiles et ses tumeurs. Lyon Chir. 1924;21:257-280.
  3. Bailey OT. The cutaneous glomus and its tumors—glomangiomas. Am J Pathol. 1935;11:915-936.
  4. Monteagudo C, Carda C, Llombart-Bosch A, et al. Multiple glomangiomyoma versus glomangioma: conceptual and ultrastructural observations. Am J Dermatopathol. 2000;22:371-373.
  5. Myers RS, Lo AK, Pawel BR. The glomangioma in the differential diagnosis of vascular malformations. Ann Plast Surg. 2006;57:443-446.
  6. Blume-Peytavi U, Adler YD, Geilen CC, et al. Multiple familial cutaneous glomangioma: a pedigree of 4 generations and critical analysis of histologic and genetic differences of glomus tumors. J Am Acad Dermatol. 2000;42:633-639.
  7. Chatterjee JS, Youssef AHK, Brown RM, et al. Congenital nodular multiple glomangioma: a case report. J Clin Pathol. 2005;58:102-103.
  8. Requena L, Galvan C, Sanchez Yus E, et al. Solitary plaque-like telangiectatic glomangioma. Br J Dermatol. 1998;139:902-905.
  9. Abou Jaoude JF, Roula Farah A, Sargi Z, et al. Glomus tumors: report on eleven cases and a review of the literature. Chir Main. 2000;19:243-252.
  10. Lu R, Krathen RA, Sanchez RL, et al. Multiple glomangiomas: potential for confusion with blue rubber bleb nevus syndrome. J Am Acad Dermatol. 2005;52:731-732.
  11. Moodley M, Ramdial P. Blue rubber bleb nevus syndrome: case report and review of the literature. Pediatrics. 1993;92:160-162.
  12. Nahm WK, Moise S, Eichenfield LF, et al. Venous malformations in blue rubber bleb nevus syndrome: variable onset of presentation. J Am Acad Dermatol. 2004;50:101-106.
  13. Boon LM, Mulliken JB, Enjolras O, et al. Glomuvenous malformation (glomangioma) and venous malformation: distinct clinicopathologic and genetic entities. Arch Dermatol. 2004;140:971-976.
  14. Vercellino N, Nozza P, Oddone M, et al. Large plaque-like glomuvenous malformation (glomangioma) simulating venous malformation. Clin Exp Dermatol. 2006;31:538-541.
References

  1. Parsi K, Kossard S. Multiple hereditary glomangiomas: successful treatment with sclerotherapy. Aust J Dermatol. 2002;43:43-47.
  2. Masson P. Le glomus neuromyo-artériel des régions tactiles et ses tumeurs. Lyon Chir. 1924;21:257-280.
  3. Bailey OT. The cutaneous glomus and its tumors—glomangiomas. Am J Pathol. 1935;11:915-936.
  4. Monteagudo C, Carda C, Llombart-Bosch A, et al. Multiple glomangiomyoma versus glomangioma: conceptual and ultrastructural observations. Am J Dermatopathol. 2000;22:371-373.
  5. Myers RS, Lo AK, Pawel BR. The glomangioma in the differential diagnosis of vascular malformations. Ann Plast Surg. 2006;57:443-446.
  6. Blume-Peytavi U, Adler YD, Geilen CC, et al. Multiple familial cutaneous glomangioma: a pedigree of 4 generations and critical analysis of histologic and genetic differences of glomus tumors. J Am Acad Dermatol. 2000;42:633-639.
  7. Chatterjee JS, Youssef AHK, Brown RM, et al. Congenital nodular multiple glomangioma: a case report. J Clin Pathol. 2005;58:102-103.
  8. Requena L, Galvan C, Sanchez Yus E, et al. Solitary plaque-like telangiectatic glomangioma. Br J Dermatol. 1998;139:902-905.
  9. Abou Jaoude JF, Roula Farah A, Sargi Z, et al. Glomus tumors: report on eleven cases and a review of the literature. Chir Main. 2000;19:243-252.
  10. Lu R, Krathen RA, Sanchez RL, et al. Multiple glomangiomas: potential for confusion with blue rubber bleb nevus syndrome. J Am Acad Dermatol. 2005;52:731-732.
  11. Moodley M, Ramdial P. Blue rubber bleb nevus syndrome: case report and review of the literature. Pediatrics. 1993;92:160-162.
  12. Nahm WK, Moise S, Eichenfield LF, et al. Venous malformations in blue rubber bleb nevus syndrome: variable onset of presentation. J Am Acad Dermatol. 2004;50:101-106.
  13. Boon LM, Mulliken JB, Enjolras O, et al. Glomuvenous malformation (glomangioma) and venous malformation: distinct clinicopathologic and genetic entities. Arch Dermatol. 2004;140:971-976.
  14. Vercellino N, Nozza P, Oddone M, et al. Large plaque-like glomuvenous malformation (glomangioma) simulating venous malformation. Clin Exp Dermatol. 2006;31:538-541.
Issue
Cutis - 83(1)
Issue
Cutis - 83(1)
Page Number
24-27
Page Number
24-27
Publications
Publications
Topics
Article Type
Display Headline
Glomangioma: A Case Report and Review of the Literature
Display Headline
Glomangioma: A Case Report and Review of the Literature
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

What's Eating You? Native and Imported Fire Ants

Article Type
Changed
Display Headline
What's Eating You? Native and Imported Fire Ants

Article PDF
Author and Disclosure Information

Klotz JH, Pinnas JL, Greenberg L, Quimayousie D, Schmidt JO, Klotz SA

Issue
Cutis - 83(1)
Publications
Topics
Page Number
17-20
Sections
Author and Disclosure Information

Klotz JH, Pinnas JL, Greenberg L, Quimayousie D, Schmidt JO, Klotz SA

Author and Disclosure Information

Klotz JH, Pinnas JL, Greenberg L, Quimayousie D, Schmidt JO, Klotz SA

Article PDF
Article PDF

Issue
Cutis - 83(1)
Issue
Cutis - 83(1)
Page Number
17-20
Page Number
17-20
Publications
Publications
Topics
Article Type
Display Headline
What's Eating You? Native and Imported Fire Ants
Display Headline
What's Eating You? Native and Imported Fire Ants
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

Erythema Toxicum Neonatorum Revisited

Article Type
Changed
Display Headline
Erythema Toxicum Neonatorum Revisited

Article PDF
Author and Disclosure Information

Morgan AJ, Steen CJ, Schwartz RA, Janniger CK

Issue
Cutis - 83(1)
Publications
Page Number
13-16
Sections
Author and Disclosure Information

Morgan AJ, Steen CJ, Schwartz RA, Janniger CK

Author and Disclosure Information

Morgan AJ, Steen CJ, Schwartz RA, Janniger CK

Article PDF
Article PDF

Issue
Cutis - 83(1)
Issue
Cutis - 83(1)
Page Number
13-16
Page Number
13-16
Publications
Publications
Article Type
Display Headline
Erythema Toxicum Neonatorum Revisited
Display Headline
Erythema Toxicum Neonatorum Revisited
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

What Is Your Diagnosis? Benign Acrospiroma

Article Type
Changed
Display Headline
What Is Your Diagnosis? Benign Acrospiroma

Article PDF
Author and Disclosure Information

Lin D, Perri AJ III, Weaver JM, Colome MI, Raimer SS

Issue
Cutis - 83(1)
Publications
Topics
Page Number
12,21-22
Sections
Author and Disclosure Information

Lin D, Perri AJ III, Weaver JM, Colome MI, Raimer SS

Author and Disclosure Information

Lin D, Perri AJ III, Weaver JM, Colome MI, Raimer SS

Article PDF
Article PDF

Issue
Cutis - 83(1)
Issue
Cutis - 83(1)
Page Number
12,21-22
Page Number
12,21-22
Publications
Publications
Topics
Article Type
Display Headline
What Is Your Diagnosis? Benign Acrospiroma
Display Headline
What Is Your Diagnosis? Benign Acrospiroma
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

New Year's Wishes [editorial]

Article Type
Changed
Display Headline
New Year's Wishes [editorial]

Article PDF
Author and Disclosure Information

Weinberg JM

Issue
Cutis - 83(1)
Publications
Page Number
10
Sections
Author and Disclosure Information

Weinberg JM

Author and Disclosure Information

Weinberg JM

Article PDF
Article PDF

Issue
Cutis - 83(1)
Issue
Cutis - 83(1)
Page Number
10
Page Number
10
Publications
Publications
Article Type
Display Headline
New Year's Wishes [editorial]
Display Headline
New Year's Wishes [editorial]
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

Surgical Treatment Option for Lower Eyelid Aging

Article Type
Changed
Display Headline
Surgical Treatment Option for Lower Eyelid Aging

Article PDF
Author and Disclosure Information

Niamtu J III

Issue
Cutis - 82(6)
Publications
Topics
Page Number
652-657
Sections
Author and Disclosure Information

Niamtu J III

Author and Disclosure Information

Niamtu J III

Article PDF
Article PDF

Issue
Cutis - 82(6)
Issue
Cutis - 82(6)
Page Number
652-657
Page Number
652-657
Publications
Publications
Topics
Article Type
Display Headline
Surgical Treatment Option for Lower Eyelid Aging
Display Headline
Surgical Treatment Option for Lower Eyelid Aging
Sections
Article Source

Citation Override
Originally published in Cosmetic Dermatology
PURLs Copyright

Inside the Article

Article PDF Media

Interest in an Emollient Containing Pentyl Rhamnoside in the Management of Xerosis and Atopic Skin

Article Type
Changed
Display Headline
Interest in an Emollient Containing Pentyl Rhamnoside in the Management of Xerosis and Atopic Skin

Article PDF
Author and Disclosure Information

Barbaud A, Dedieu F, Mery S, Sibaud V, Merial-Kieny C

Issue
Cutis - 82(6)
Publications
Topics
Page Number
647-651
Sections
Author and Disclosure Information

Barbaud A, Dedieu F, Mery S, Sibaud V, Merial-Kieny C

Author and Disclosure Information

Barbaud A, Dedieu F, Mery S, Sibaud V, Merial-Kieny C

Article PDF
Article PDF

Issue
Cutis - 82(6)
Issue
Cutis - 82(6)
Page Number
647-651
Page Number
647-651
Publications
Publications
Topics
Article Type
Display Headline
Interest in an Emollient Containing Pentyl Rhamnoside in the Management of Xerosis and Atopic Skin
Display Headline
Interest in an Emollient Containing Pentyl Rhamnoside in the Management of Xerosis and Atopic Skin
Sections
Article Source

Citation Override
Originally published in Cosmetic Dermatology
PURLs Copyright

Inside the Article

Article PDF Media

Optimizing Results of Nonsurgical Cosmetic Procedures With a Topical Skin Care Regimen

Article Type
Changed
Display Headline
Optimizing Results of Nonsurgical Cosmetic Procedures With a Topical Skin Care Regimen

Article PDF
Author and Disclosure Information

Narurkar VA

Issue
Cutis - 82(6)
Publications
Topics
Page Number
641-644
Sections
Author and Disclosure Information

Narurkar VA

Author and Disclosure Information

Narurkar VA

Article PDF
Article PDF

Issue
Cutis - 82(6)
Issue
Cutis - 82(6)
Page Number
641-644
Page Number
641-644
Publications
Publications
Topics
Article Type
Display Headline
Optimizing Results of Nonsurgical Cosmetic Procedures With a Topical Skin Care Regimen
Display Headline
Optimizing Results of Nonsurgical Cosmetic Procedures With a Topical Skin Care Regimen
Sections
Article Source

Citation Override
Originally published in Cosmetic Dermatology
PURLs Copyright

Inside the Article

Article PDF Media

The Treatment of Melasma: Which Drugs Are Effective? [letter]

Article Type
Changed
Display Headline
The Treatment of Melasma: Which Drugs Are Effective? [letter]

Article PDF
Author and Disclosure Information

Hernández-Pérez E, Hernández-Pérez JE, Hernández-Pérez M, Khawaja HA

Issue
Cutis - 82(6)
Publications
Topics
Page Number
638-640
Sections
Author and Disclosure Information

Hernández-Pérez E, Hernández-Pérez JE, Hernández-Pérez M, Khawaja HA

Author and Disclosure Information

Hernández-Pérez E, Hernández-Pérez JE, Hernández-Pérez M, Khawaja HA

Article PDF
Article PDF

Issue
Cutis - 82(6)
Issue
Cutis - 82(6)
Page Number
638-640
Page Number
638-640
Publications
Publications
Topics
Article Type
Display Headline
The Treatment of Melasma: Which Drugs Are Effective? [letter]
Display Headline
The Treatment of Melasma: Which Drugs Are Effective? [letter]
Sections
Article Source

Citation Override
Originally published in Cosmetic Dermatology
PURLs Copyright

Inside the Article

Article PDF Media